Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06475755

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

A Phase II, Prospective, Randomized, Open Label, Multi-center Study of Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant With Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Sponsor: Tang-Du Hospital

Conditions Anti Angiogenesis Non-Small Cell Lung Cancer

Interventions Immunochemotherapy Immunochemotherapy combined with antiangiogenic

Updated 2 times since 2024 Last updated: Jun 20, 2024 Started: Jun 30, 2024 Primary completion: Jun 10, 2025 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anti Angiogenesis and Non-Small Cell Lung Cancer and is currently actively recruiting participants. Tang-Du Hospital leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tang-Du Hospital

Data source: Tang-Du Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China